Coherus Oncology (CHRS) Total Debt (2014 - 2026)

Coherus Oncology has disclosed Total Debt across 13 years of filings, most recently posting $37.1 million for Q1 2026.

• Total Debt for Q1 2026 came in at $37.1 million, down 41.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.1 million (down 41.04% YoY), and the FY2025 annual result was $37.1 million, down 26.37% from the prior year.
• Total Debt came in at $37.1 million for Q1 2026 at Coherus Oncology, roughly flat from $37.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $250.3 million in Q3 2023 to a low of $36.9 million in Q2 2025.
• The 5-year median for Total Debt is $72.5 million (2024), against an average of $135.3 million.
• Across the five-year window, Total Debt surged 225.99% in 2022 and tumbled 81.69% in 2024, its largest moves.
• Coherus Oncology's Total Debt stood at $245.5 million in 2022, then grew by 1.75% to $249.8 million in 2023, then tumbled by 79.86% to $50.3 million in 2024, then slipped by 26.37% to $37.1 million in 2025, then increased by 0.26% to $37.1 million in 2026.
• The last three Total Debt figures came in at $37.1 million (Q1 2026), $37.1 million (Q4 2025), and $37.0 million (Q3 2025), per Business Quant data.